CN106421765A - 一种用于治疗皮肤瘙痒的膏药 - Google Patents
一种用于治疗皮肤瘙痒的膏药 Download PDFInfo
- Publication number
- CN106421765A CN106421765A CN201611010577.6A CN201611010577A CN106421765A CN 106421765 A CN106421765 A CN 106421765A CN 201611010577 A CN201611010577 A CN 201611010577A CN 106421765 A CN106421765 A CN 106421765A
- Authority
- CN
- China
- Prior art keywords
- parts
- plaster
- treating skin
- skin pruritus
- olive oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 57
- 239000011505 plaster Substances 0.000 title claims abstract description 40
- 239000004006 olive oil Substances 0.000 claims abstract description 19
- 235000008390 olive oil Nutrition 0.000 claims abstract description 19
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 18
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims abstract description 18
- 229960003657 dexamethasone acetate Drugs 0.000 claims abstract description 18
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 17
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 17
- 239000004410 anthocyanin Substances 0.000 claims abstract description 17
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 17
- 102000007625 Hirudins Human genes 0.000 claims abstract description 14
- 108010007267 Hirudins Proteins 0.000 claims abstract description 14
- 229940006607 hirudin Drugs 0.000 claims abstract description 14
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 14
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960000520 diphenhydramine Drugs 0.000 claims abstract description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 21
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 17
- 244000287839 Vaccinium bracteatum Species 0.000 claims description 17
- 235000005480 Vaccinium bracteatum Nutrition 0.000 claims description 17
- 229960003291 chlorphenamine Drugs 0.000 claims description 17
- 239000002023 wood Substances 0.000 claims description 17
- 244000017020 Ipomoea batatas Species 0.000 claims description 16
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- 230000008020 evaporation Effects 0.000 claims description 9
- 238000001704 evaporation Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 206010063409 Acarodermatitis Diseases 0.000 claims 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 claims 1
- 241000447727 Scabies Species 0.000 claims 1
- 208000005687 scabies Diseases 0.000 claims 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 claims 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 12
- 201000004624 Dermatitis Diseases 0.000 abstract description 6
- 229960001340 histamine Drugs 0.000 abstract description 6
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 abstract 1
- 235000004976 Solanum vernei Nutrition 0.000 abstract 1
- 241000352057 Solanum vernei Species 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000010081 allicin Nutrition 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 229940072350 chlor-trimeton Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229940056692 resinol Drugs 0.000 abstract 1
- 230000002568 urticarial effect Effects 0.000 abstract 1
- 239000012467 final product Substances 0.000 description 6
- 238000007705 chemical test Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010048768 Dermatosis Diseases 0.000 description 2
- 208000036741 Pruritus generalised Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种用于治疗皮肤瘙痒的膏药，所述用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素8‑12份、大蒜素11‑14份、烟酰胺4‑8份、紫薯花青素5‑10份、橄榄油12‑17份、醋酸地塞米松29‑34份、杜米芬15‑30份、苯海拉明11‑17份、南烛木树脂酚18‑22份、扑尔敏10‑17份。本发明的药物不仅对内源性组胺具有抑制作用，而且对外源性组胺也有拮抗活性，从而通过抑制组胺的释放而发挥缓解全身皮肤瘙痒的药理作用，可用于皮炎、湿疹、荨麻疹等皮肤瘙痒性疾病的治疗。
Description
技术领域
本发明涉及一种医药技术领域，具体是一种用于治疗皮肤瘙痒的膏药。
背景技术
瘙痒症(pruritus)是一种自觉瘙痒而临床上无原发损害的皮肤病，是临床上常见的皮肤病之一，其特征为以瘙痒为主，而无原发性损害。临床上可分为局部性和全身性两种。局部性瘙痒症常见于肛门、阴部或四肢等，局部仅自觉瘙痒，并无皮疹，日久可致皮肤增厚，湿疹样改变。肛管及肛门周围顽固性瘙痒是本病的主要症状，初起时一般限于肛门周围皮肤瘙痒，多为阵发性，瘙痒的程度轻重不一，如长期不愈，有的可蔓延至阴囊或阴唇，尤其是在会阴部前后缝间瘙痒更甚，夜间更为显著，有时如虫爬、蚁走；有时如蚊咬、火烤，使人难以入眠，坐卧不宁，无法忍耐。全身性瘙痒症病人全身各处皆有痒的感觉，但不是全身同时发痒，往往由一处移到另一处。发痒的程度不尽相同，有人虽然觉得皮肤发痒，但仍可以忍受，有的病人觉得全身奇痒，需用铁刷子刷皮肤或热水洗烫，直至皮肤出血而感觉疼痛及灼痛时，痒觉才暂时减轻。往往以晚间痒重，患者因发痒而失眠或不能安眠。由于剧烈瘙痒，不断搔抓，可以出现抓痕、血痂、或条状的抓伤，有时有湿疹样改变，苔藓样变或色素沉着。抓伤的皮肤也容易感染而发生疖肿或毛囊炎。局部性或全身性瘙痒症的治疗，临床上也有不少治疗方法，通过口服各类中西药物或外用止痒剂，都可使瘙痒缓解和得到治愈。但其中约有30％左右的瘙痒症患者为顽固性瘙痒症。虽然使用药物但经久不愈或反复发作，治疗成本高，使用方法复杂。
发明内容
本发明的目的在于提供一种用于治疗皮肤瘙痒的膏药，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素8-12份、大蒜素11-14份、烟酰胺4-8份、紫薯花青素5-10份、橄榄油12-17份、醋酸地塞米松29-34份、杜米芬15-30份、苯海拉明11-17份、南烛木树脂酚18-22份、扑尔敏10-17份。
作为本发明进一步的方案：所述用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素9-11份、大蒜素12-13份、烟酰胺5-7份、紫薯花青素6-8份、橄榄油13-16份、醋酸地塞米松30-32份、杜米芬18-24份、苯海拉明12-16份、南烛木树脂酚20-21份、扑尔敏13-15份。
作为本发明进一步的方案：所述用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素10份、大蒜素13份、烟酰胺6份、紫薯花青素7份、橄榄油15份、醋酸地塞米松31份、杜米芬21份、苯海拉明14份、南烛木树脂酚21份、扑尔敏14份。
一种用于治疗皮肤瘙痒的膏药的制备方法，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在150-180r/min，搅拌结束后，于40-60℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
作为本发明进一步的方案：具体步骤中搅拌速度控制在170r/min。
作为本发明进一步的方案：具体步骤中于50℃下蒸发浓缩。
与现有技术相比，本发明的有益效果是：
本发明的药物不仅对内源性组胺具有抑制作用，而且对外源性组胺也有拮抗活性，从而通过抑制组胺的释放而发挥缓解全身皮肤瘙痒的药理作用，可用于皮炎、湿疹、荨麻疹等皮肤瘙痒性疾病的治疗。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素8份、大蒜素11份、烟酰胺4份、紫薯花青素5份、橄榄油12份、醋酸地塞米松29份、杜米芬15份、苯海拉明11份、南烛木树脂酚18份、扑尔敏10份。
一种用于治疗皮肤瘙痒的膏药的制备方法，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在150r/min，搅拌结束后，于40℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
实施例2
一种用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为水蛭素9份、大蒜素12份、烟酰胺5份、紫薯花青素6份、橄榄油13份、醋酸地塞米松30份、杜米芬18份、苯海拉明12份、南烛木树脂酚20份、扑尔敏13份。
一种用于治疗皮肤瘙痒的膏药的制备方法，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在150r/min，搅拌结束后，于40℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
实施例3
一种用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素10份、大蒜素13份、烟酰胺6份、紫薯花青素7份、橄榄油15份、醋酸地塞米松31份、杜米芬21份、苯海拉明14份、南烛木树脂酚21份、扑尔敏14份。
一种用于治疗皮肤瘙痒的膏药的制备方法，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在170r/min，搅拌结束后，于50℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
实施例4
一种用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素11份、大蒜素13份、烟酰胺7份、紫薯花青素8份、橄榄油16份、醋酸地塞米松32份、杜米芬24份、苯海拉明16份、南烛木树脂酚21份、扑尔敏15份。
一种用于治疗皮肤瘙痒的膏药的制备方法，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在180r/min，搅拌结束后，于60℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
实施例5
一种用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素12份、大蒜素14份、烟酰胺8份、紫薯花青素10份、橄榄油17份、醋酸地塞米松34份、杜米芬30份、苯海拉明17份、南烛木树脂酚22份、扑尔敏17份。
一种用于治疗皮肤瘙痒的膏药的制备方法，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在180r/min，搅拌结束后，于60℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
临床实验：
(1)临床资料：本发明人对100例皮肤瘙痒患者进行临床观察治疗，其中男50例，女50例，年龄在22～65岁之间。
(2)治疗方法：每天涂抹6次，每次涂抹500mg。药量采用根据患者实际情况在本发明各药量区间内进行调节，通常轻度患者采用实施例1膏药，中度患者采用实施例3膏药，重病患者采用实施例5膏药。
(3)疗效判定标准：
治愈：症状全部消失；主要理化检测指标均为正常。
显效：全部症状消除或主要症状消除；理化检测指标基本正常。
有效：主要症状基本消失；主要理化检测指标有所改善
无效：主要理化检测指标与治疗前无变化。
(4)临床结果：
临床治愈96例(96％)，显效3例(3％)，有效1例(1％)，总有效率为100％。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (6)
1.一种用于治疗皮肤瘙痒的膏药，其特征在于，按照重量份的主要原料为：水蛭素8-12份、大蒜素11-14份、烟酰胺4-8份、紫薯花青素5-10份、橄榄油12-17份、醋酸地塞米松29-34份、杜米芬15-30份、苯海拉明11-17份、南烛木树脂酚18-22份、扑尔敏10-17份。
2.根据权利要求1所述的用于治疗皮肤瘙痒的膏药，其特征在于，所述用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素9-11份、大蒜素12-13份、烟酰胺5-7份、紫薯花青素6-8份、橄榄油13-16份、醋酸地塞米松30-32份、杜米芬18-24份、苯海拉明12-16份、南烛木树脂酚20-21份、扑尔敏13-15份。
3.根据权利要求1或2所述的用于治疗皮肤瘙痒的膏药，其特征在于，所述用于治疗皮肤瘙痒的膏药，按照重量份的主要原料为：水蛭素10份、大蒜素13份、烟酰胺6份、紫薯花青素7份、橄榄油15份、醋酸地塞米松31份、杜米芬21份、苯海拉明14份、南烛木树脂酚21份、扑尔敏14份。
4.一种如权利要求1-3任一所述的用于治疗皮肤瘙痒的膏药的制备方法，其特征在于，具体步骤为：
首先，将水蛭素、大蒜素、烟酰胺、紫薯花青素、橄榄油、醋酸地塞米松、杜米芬、苯海拉明、南烛木树脂酚、扑尔敏混匀，不断加水搅拌，搅拌速度控制在150-180r/min，搅拌结束后，于40-60℃下蒸发浓缩，直至浓缩物的密度达到1.12-1.13g/cm3，装入软膏管中，即得用于治疗皮肤瘙痒的膏药。
5.根据权利要求4所述的用于治疗皮肤瘙痒的膏药的制备方法，其特征在于，具体步骤中搅拌速度控制在170r/min。
6.根据权利要求4所述的用于治疗皮肤瘙痒的膏药的制备方法，其特征在于，具体步骤中于50℃下蒸发浓缩。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611010577.6A CN106421765A (zh) | 2016-11-17 | 2016-11-17 | 一种用于治疗皮肤瘙痒的膏药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611010577.6A CN106421765A (zh) | 2016-11-17 | 2016-11-17 | 一种用于治疗皮肤瘙痒的膏药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106421765A true CN106421765A (zh) | 2017-02-22 |
Family
ID=58220691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611010577.6A Withdrawn CN106421765A (zh) | 2016-11-17 | 2016-11-17 | 一种用于治疗皮肤瘙痒的膏药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106421765A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264070A (zh) * | 2008-04-25 | 2008-09-17 | 梁勇才 | 一种治疗皮肤病的药物及其制备方法 |
| CN102813660A (zh) * | 2012-09-13 | 2012-12-12 | 前郭尔罗斯蒙古族自治县医院 | 一种治疗皮肤湿疹的外用药物 |
| CN104688853A (zh) * | 2015-03-02 | 2015-06-10 | 张小安 | 一种治疗各种皮肤瘙痒症的中西药组合物及其制备方法 |
-
2016
- 2016-11-17 CN CN201611010577.6A patent/CN106421765A/zh not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264070A (zh) * | 2008-04-25 | 2008-09-17 | 梁勇才 | 一种治疗皮肤病的药物及其制备方法 |
| CN102813660A (zh) * | 2012-09-13 | 2012-12-12 | 前郭尔罗斯蒙古族自治县医院 | 一种治疗皮肤湿疹的外用药物 |
| CN104688853A (zh) * | 2015-03-02 | 2015-06-10 | 张小安 | 一种治疗各种皮肤瘙痒症的中西药组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101785836B (zh) | 一种治疗皮肤病的中药膏剂及其制备方法和应用 | |
| CN104547303A (zh) | 一种治疗妇科炎症的外用凝胶剂及其制备方法 | |
| CN106421765A (zh) | 一种用于治疗皮肤瘙痒的膏药 | |
| CN109223860A (zh) | 一种复方五行草喷剂 | |
| CN103285238B (zh) | 一种止血的中药 | |
| CN102688345B (zh) | 一种治疗口腔溃疡的复合膜及其制备方法 | |
| CN104800597A (zh) | 一种治疗咽喉炎的中药组合物 | |
| CN106390104A (zh) | 一种治疗皮肤瘙痒的膏药 | |
| CN103751245B (zh) | 一种治疗皮肤病的中药组合物及其用途 | |
| CN103933068A (zh) | 一种止痒抗过敏软膏及其制备方法 | |
| CN111407770B (zh) | 一种治疗皮肤病的组合物及其应用 | |
| CN101433542A (zh) | 一种治疗人急性放射性食管炎的内服药物 | |
| CN105998541A (zh) | 一种治疗痔疮的外用药物及其应用 | |
| CN108392495A (zh) | 止痒消炎软膏 | |
| CN103830372B (zh) | 一种治疗痔疮的中药组合物及其制备方法 | |
| CN104027425B (zh) | 一种治疗痤疮的外用药及其制备方法 | |
| CN112315863B (zh) | 一种舒缓光电术中疼痛热感的组合物及制备方法和应用 | |
| CN103908508B (zh) | 一种脚气康复药剂 | |
| KR20100083920A (ko) | 식물성 화상 치료제 | |
| CN107308220A (zh) | 一种治疗口腔粘膜疾病的组合物 | |
| CN118319989A (zh) | 一种清热燥湿、祛风止痒的外用中药组合物 | |
| CN106236953A (zh) | 一种治疗痔疮的膏药 | |
| CN111067938A (zh) | 一种治疗鼻炎的中药配方及其制备方法 | |
| Raximberganov et al. | Experimental studies in development of suppositories of coloproctological application | |
| KR20230017469A (ko) | 치질 연고 및 이의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |